Sana Biotechnology, Inc. - Revizia istoricului

127.0.0.1: The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

2024-10-03T05:07:03Z

The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

← Versiunea anterioară		Versiunea de la data 3 octombrie 2024 08:07
Linia 2:		Linia 2:

	==Descriere companie==		==Descriere companie==
	Sana Biotechnology, Inc (https://sana.com/) is a preclinical-stage biotechnology company. The Company is focused on creating and delivering engineered cells as medicines for patients. The Company develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders, among others. The Company’s process of repairing and controlling genes in the body, referred to as gene therapy or in vivo cell engineering, requires in vivo delivery of a therapeutic payload and modification of the genome. The Company’s fusogen technology in preclinical studies targets cell surface receptors when combined with delivery vehicles to form fusosomes and allows cell-specific delivery across multiple different cell types. It focuses this technology on delivering payloads to T cells, hepatocytes, and hematopoietic stem cells (HSCs).		Sana Biotechnology, Inc (https://sana.com/) is a preclinical-stage biotechnology company. The Company is focused on creating and delivering engineered cells as medicines for patients. The Company develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, [[CENTRAL\|central]] nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders, among others. The Company’s process of repairing and controlling genes in the body, referred to as gene therapy or in vivo cell engineering, requires in vivo delivery of a therapeutic payload and modification of the genome. The Company’s fusogen technology in preclinical studies targets cell surface receptors when combined with delivery vehicles to form fusosomes and allows cell-specific delivery across multiple different cell types. It focuses this technology on delivering payloads to T cells, hepatocytes, and hematopoietic stem cells (HSCs).

	==Grafic actiuni companie==		==Grafic actiuni companie==

Admin: Pagină nouă: Pagina dedicata companiei Sana Biotechnology, Inc. listata cu simbolul US.SANA ==Descriere companie== Sana Biotechnology, Inc (https://sana.com/) is a preclinical-stage biotechnology company. The Company is focused on creating and delivering engineered cells as medicines for patients. The Company develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous...

2024-09-18T18:27:02Z

Pagină nouă: Pagina dedicata companiei Sana Biotechnology, Inc. listata cu simbolul US.SANA ==Descriere companie== Sana Biotechnology, Inc (https://sana.com/) is a preclinical-stage biotechnology company. The Company is focused on creating and delivering engineered cells as medicines for patients. The Company develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous...

Pagină nouă

Pagina dedicata companiei Sana Biotechnology, Inc. listata cu simbolul US.SANA

==Descriere companie==
Sana Biotechnology, Inc (https://sana.com/) is a preclinical-stage biotechnology company. The Company is focused on creating and delivering engineered cells as medicines for patients. The Company develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders, among others. The Company’s process of repairing and controlling genes in the body, referred to as gene therapy or in vivo cell engineering, requires in vivo delivery of a therapeutic payload and modification of the genome. The Company’s fusogen technology in preclinical studies targets cell surface receptors when combined with delivery vehicles to form fusosomes and allows cell-specific delivery across multiple different cell types. It focuses this technology on delivering payloads to T cells, hepatocytes, and hematopoietic stem cells (HSCs).

==Grafic actiuni companie==
<iframe key="tradeville" path="graficSimbol/US.SANA" />

==Ultimele stiri despre Sana Biotechnology, Inc. (US.SANA)==
<dynamicpagelist>
category=US.SANA
count=10
order=descending
addfirstcategorydate=false
</dynamicpagelist>

[[Categorie:US.SANA]][[Categorie:Stiri despre companii]]